|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Travis WD: Pathology of lung cancer. Clin
Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang X, Yang K and Kuang K: The efficacy
and safety of EGFR inhibitor monotherapy in non-small cell lung
cancer: A systematic review. Curr Oncol Rep. 16:3902014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rossi A, Maione P, Sacco PC, Sgambato A,
Casaluce F, Ferrara ML, Palazzolo G, Ciardiello F and Gridelli C:
ALK inhibitors and advanced non-small cell lung cancer (Review).
Int J Oncol. 45:499–508. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Inamura K: Diagnostic and therapeutic
potential of microRNAs in lung cancer. Cancers (Basel). 9:92017.
View Article : Google Scholar :
|
|
6
|
Groome PA, Bolejack V, Crowley JJ, Kennedy
C, Krasnik M, Sobin LH and Goldstraw P; IASLC International Staging
Committee; Cancer Research and Biostatistics; Observers to the
Committee, : Participating Institutions: The IASLC Lung Cancer
Staging Project: Validation of the proposals for revision of the
TN, and M descriptors and consequent stage groupings in the
forthcoming (seventh) edition of the TNM classification of
malignant tumours. J Thorac Oncol. 2:694–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen JJ, Peck K, Hong TM, Yang SC, Sher
YP, Shih JY, Wu R, Cheng JL, Roffler SR, Wu CW, et al: Global
analysis of gene expression in invasion by a lung cancer model.
Cancer Res. 61:5223–5230. 2001.PubMed/NCBI
|
|
8
|
Yang Y, Liu Y, He JC, Wang JM, Schemmer P,
Ma CQ, Qian YW, Yao W, Zhang J, Qi WP, et al: 14-3-3ζ and aPKC-ι
synergistically facilitate epithelial-mesenchymal transition of
cholangiocarcinoma via GSK-3β/Snail signaling pathway. Oncotarget.
7:55191–55210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang XY, Ke AW, Shi GM, Zhang X, Zhang C,
Shi YH, Wang XY, Ding ZB, Xiao YS, Yan J, et al: αB-crystallin
complexes with 14-3-3ζ to induce epithelial-mesenchymal transition
and resistance to sorafenib in hepatocellular carcinoma.
Hepatology. 57:2235–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang Y, Liu S, Li N, Guo W, Shi J, Yu H,
Zhang L, Wang K, Liu S and Cheng S: 14-3-3ζ promotes hepatocellular
carcinoma venous metastasis by modulating hypoxia-inducible
factor-1α. Oncotarget. 7:15854–15867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rüenauver K, Menon R, Svensson MA,
Carlsson J, Vogel W, Andrén O, Nowak M and Perner S: Prognostic
significance of YWHAZ expression in localized prostate cancer.
Prostate Cancer Prostatic Dis. 17:310–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nishimura Y, Komatsu S, Ichikawa D, Nagata
H, Hirajima S, Takeshita H, Kawaguchi T, Arita T, Konishi H,
Kashimoto K, et al: Overexpression of YWHAZ relates to tumor cell
proliferation and malignant outcome of gastric carcinoma. Br J
Cancer. 108:1324–1331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matta A, DeSouza LV, Shukla NK, Gupta SD,
Ralhan R and Siu KW: Prognostic significance of head-and-neck
cancer biomarkers previously discovered and identified using
iTRAQ-labeling and multidimensional liquid chromatography-tandem
mass spectrometry. J Proteome Res. 7:2078–2087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Neal CL, Yao J, Yang W, Zhou X, Nguyen NT,
Lu J, Danes CG, Guo H, Lan KH, Ensor J, et al: 14-3-3zeta
overexpression defines high risk for breast cancer recurrence and
promotes cancer cell survival. Cancer Res. 69:3425–3432. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rajabi H, Ahmad R, Jin C, Joshi MD, Guha
M, Alam M, Kharbanda S and Kufe D: MUC1-C oncoprotein confers
androgen-independent growth of human prostate cancer cells.
Prostate. 72:1659–1668. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: a new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahmad R, Raina D, Joshi MD, Kawano T, Ren
J, Kharbanda S and Kufe D: MUC1-C oncoprotein functions as a direct
activator of the nuclear factor-kappaB p65 transcription factor.
Cancer Res. 69:7013–7021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang Y, Lv P, Sun Z, Han L, Luo B and Zhou
W: 14-3-3ζ up-regulates hypoxia-inducible factor-1α in
hepatocellular carcinoma via activation of PI3K/Akt/NF-κB signal
transduction pathway. Int J Clin Exp Pathol. 8:15845–15853.
2015.PubMed/NCBI
|
|
19
|
Tong S, Xia T, Fan K, Jiang K, Zhai W, Li
JS, Wang SH and Wang JJ: 14-3-3ζ promotes lung cancer cell invasion
by increasing the Snail protein expression through atypical protein
kinase C (aPKC)/NF-κB signaling. Exp Cell Res. 348:1–9. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rajabi H, Alam M, Takahashi H, Kharbanda
A, Guha M, Ahmad R and Kufe D: MUC1-C oncoprotein activates the
ZEB1/miR-200c regulatory loop and epithelial-mesenchymal
transition. Oncogene. 33:1680–1689. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roy LD, Sahraei M, Subramani DB, Besmer D,
Nath S, Tinder TL, Bajaj E, Shanmugam K, Lee YY, Hwang SI, et al:
MUC1 enhances invasiveness of pancreatic cancer cells by inducing
epithelial to mesenchymal transition. Oncogene. 30:1449–1459. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen CH, Chuang SM, Yang MF, Liao JW, Yu
SL and Chen JJ: A novel function of YWHAZ/β-catenin axis in
promoting epithelial-mesenchymal transition and lung cancer
metastasis. Mol Cancer Res. 10:1319–1331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shedden K, Taylor JM, Enkemann SA, Tsao
MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ,
Misek DE, et al: Director's Challenge Consortium for the Molecular
Classification of Lung Adenocarcinoma: Gene expression-based
survival prediction in lung adenocarcinoma: A multi-site, blinded
validation study. Nat Med. 14:822–827. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Booth CM and Shepherd FA: Adjuvant
chemotherapy for resected non-small cell lung cancer. J Thorac
Oncol. 1:180–187. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gandara DR, Wakelee H, Calhoun R and
Jablons D: Adjuvant chemotherapy of stage I non-small cell lung
cancer in North America. J Thorac Oncol. 2 Suppl 3:S125–S127. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Situ D, Wang J, Ma Y, Zhu Z, Hu Y, Long H
and Rong T: Expression and prognostic relevance of MUC1 in stage IB
non-small cell lung cancer. Med Oncol. 28 Suppl 1:S596–S604. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
